The sunset of somatic genetics and the dawn of epigenetics: A new frontier in pancreatic cancer research

Gwen Lomberk, Angela J. Mathison, Adrienne Grzenda, Raul Urrutia

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Purpose of review. The excitement of finding a cancer modulator which is either mutated or deleted in vivo (genetics), unfortunately, is shadowed by the fact that we scientists have failed to live to the promise of gene therapy, and therefore, these genes cannot be replaced to cure the patients. On the contrary, both DNA methylation and chromatin-mediated inactivation of tumor suppressor genes (epigenetics), for example, are reversible as demonstrated by the relative success of emerging therapies. Therefore, epigenetics with its molecular basis (DNA methylation and chromatin modification) is among the most promising areas of cancer research and is a nascent field in pancreatic cancer research. Recent findings. Here, we review and update novel findings on epigenetics as it applies to pancreatic cancer. Summary. Special focus has been given to novel potential therapeutic targets and currently available drugs, which are emerging from this exciting new field of pancreatic cancer research.

Original languageEnglish (US)
Pages (from-to)597-602
Number of pages6
JournalCurrent Opinion in Gastroenterology
Volume24
Issue number5
DOIs
StatePublished - Sep 2008

Fingerprint

Pancreatic Neoplasms
Epigenomics
DNA Methylation
Chromatin
Research
Tumor Suppressor Genes
Genetic Therapy
Neoplasms
Therapeutics
Pharmaceutical Preparations
Genes

Keywords

  • Chromatin-modifying proteins
  • Epigenetics
  • Heterochromatin protein 1
  • Pancreatic cancer
  • Polycomb

ASJC Scopus subject areas

  • Gastroenterology

Cite this

The sunset of somatic genetics and the dawn of epigenetics : A new frontier in pancreatic cancer research. / Lomberk, Gwen; Mathison, Angela J.; Grzenda, Adrienne; Urrutia, Raul.

In: Current Opinion in Gastroenterology, Vol. 24, No. 5, 09.2008, p. 597-602.

Research output: Contribution to journalArticle

Lomberk, Gwen ; Mathison, Angela J. ; Grzenda, Adrienne ; Urrutia, Raul. / The sunset of somatic genetics and the dawn of epigenetics : A new frontier in pancreatic cancer research. In: Current Opinion in Gastroenterology. 2008 ; Vol. 24, No. 5. pp. 597-602.
@article{30b35c6e81b34f689c567aa32156b01b,
title = "The sunset of somatic genetics and the dawn of epigenetics: A new frontier in pancreatic cancer research",
abstract = "Purpose of review. The excitement of finding a cancer modulator which is either mutated or deleted in vivo (genetics), unfortunately, is shadowed by the fact that we scientists have failed to live to the promise of gene therapy, and therefore, these genes cannot be replaced to cure the patients. On the contrary, both DNA methylation and chromatin-mediated inactivation of tumor suppressor genes (epigenetics), for example, are reversible as demonstrated by the relative success of emerging therapies. Therefore, epigenetics with its molecular basis (DNA methylation and chromatin modification) is among the most promising areas of cancer research and is a nascent field in pancreatic cancer research. Recent findings. Here, we review and update novel findings on epigenetics as it applies to pancreatic cancer. Summary. Special focus has been given to novel potential therapeutic targets and currently available drugs, which are emerging from this exciting new field of pancreatic cancer research.",
keywords = "Chromatin-modifying proteins, Epigenetics, Heterochromatin protein 1, Pancreatic cancer, Polycomb",
author = "Gwen Lomberk and Mathison, {Angela J.} and Adrienne Grzenda and Raul Urrutia",
year = "2008",
month = "9",
doi = "10.1097/MOG.0b013e32830b111d",
language = "English (US)",
volume = "24",
pages = "597--602",
journal = "Current Opinion in Gastroenterology",
issn = "0267-1379",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - The sunset of somatic genetics and the dawn of epigenetics

T2 - A new frontier in pancreatic cancer research

AU - Lomberk, Gwen

AU - Mathison, Angela J.

AU - Grzenda, Adrienne

AU - Urrutia, Raul

PY - 2008/9

Y1 - 2008/9

N2 - Purpose of review. The excitement of finding a cancer modulator which is either mutated or deleted in vivo (genetics), unfortunately, is shadowed by the fact that we scientists have failed to live to the promise of gene therapy, and therefore, these genes cannot be replaced to cure the patients. On the contrary, both DNA methylation and chromatin-mediated inactivation of tumor suppressor genes (epigenetics), for example, are reversible as demonstrated by the relative success of emerging therapies. Therefore, epigenetics with its molecular basis (DNA methylation and chromatin modification) is among the most promising areas of cancer research and is a nascent field in pancreatic cancer research. Recent findings. Here, we review and update novel findings on epigenetics as it applies to pancreatic cancer. Summary. Special focus has been given to novel potential therapeutic targets and currently available drugs, which are emerging from this exciting new field of pancreatic cancer research.

AB - Purpose of review. The excitement of finding a cancer modulator which is either mutated or deleted in vivo (genetics), unfortunately, is shadowed by the fact that we scientists have failed to live to the promise of gene therapy, and therefore, these genes cannot be replaced to cure the patients. On the contrary, both DNA methylation and chromatin-mediated inactivation of tumor suppressor genes (epigenetics), for example, are reversible as demonstrated by the relative success of emerging therapies. Therefore, epigenetics with its molecular basis (DNA methylation and chromatin modification) is among the most promising areas of cancer research and is a nascent field in pancreatic cancer research. Recent findings. Here, we review and update novel findings on epigenetics as it applies to pancreatic cancer. Summary. Special focus has been given to novel potential therapeutic targets and currently available drugs, which are emerging from this exciting new field of pancreatic cancer research.

KW - Chromatin-modifying proteins

KW - Epigenetics

KW - Heterochromatin protein 1

KW - Pancreatic cancer

KW - Polycomb

UR - http://www.scopus.com/inward/record.url?scp=55549090720&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=55549090720&partnerID=8YFLogxK

U2 - 10.1097/MOG.0b013e32830b111d

DO - 10.1097/MOG.0b013e32830b111d

M3 - Article

C2 - 19122501

AN - SCOPUS:55549090720

VL - 24

SP - 597

EP - 602

JO - Current Opinion in Gastroenterology

JF - Current Opinion in Gastroenterology

SN - 0267-1379

IS - 5

ER -